Axsome Therapeutics (AXSM) Change in Accured Expenses (2015 - 2026)

Axsome Therapeutics' Change in Accured Expenses history runs 12 years deep, the most recent figure standing at $17.2 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses rose 2006.23% year-over-year to $17.2 million; the TTM figure through Mar 2026 stood at $100.2 million (up 53.38% YoY), while the FY2025 annual figure was $83.7 million, up 49.37% from the prior year.
• Change in Accured Expenses came in at $17.2 million for Q1 2026 at Axsome Therapeutics, up from $7.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $54.2 million in Q3 2025 to a low of -$8.4 million in Q1 2024.
• A 5-year average of $14.0 million and a median of $11.4 million in 2023 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses soared 8238.14% in 2022 and sank 217.81% in 2024, its largest moves.
• Axsome Therapeutics' Change in Accured Expenses stood at $13.2 million in 2022, then fell by 13.91% to $11.4 million in 2023, then surged by 125.95% to $25.7 million in 2024, then tumbled by 72.05% to $7.2 million in 2025, then surged by 140.16% to $17.2 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $17.2 million, $7.2 million, and $54.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison